- Global Pharma News & Resources

New Technologies Arise to Help Prevent the Spread of Diseases

- News Commentary

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- Due to increasing awareness amongst consumers on hygiene and preventive healthcare, the global surface disinfectant market is anticipated to grow significantly in the coming years. The current pandemic has caused major changes, disrupting healthcare systems all over the world, with hospitals being overwhelmed due to the increasing number of patients. MarketsandMarkets indicates that most chemical disinfectants currently available in the market have toxic properties. For example, sodium hypochlorite is an effective treatment against blood-borne pathogens but is also highly corrosive and a respiratory irritant, which makes it dangerous to cleaning personnel and building occupants, damaging to many surfaces, and toxic when released into the environment. On the other hand, a new segment has come into play, the UV disinfection equipment market. According to Grand View Research, the Defense Research and Development Organisation (DRDO) has launched UV Blaster, which is useful for disinfecting high-tech surfaces and areas with a large flow of people, such as airports, hotels, offices, metros, shopping malls, and factories. Its ease of installation and low maintenance, supervision, and space requirements have also led to the growing demand for this technology. In addition, the equipment also provides improved safety, minimum service time, and low sensitivity to pH and temperature variations compared to traditional disinfection technologies, such as chlorination. Optec International, Inc. (OTC: OPTI), Relief Therapeutics Holding AG (OTC: RLFTF), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), Novan, Inc. (NASDAQ: NOVN)

More generally, the current pandemic has prompted biotech companies to work on vaccines and possible treatments while medical device companies progress on patient monitoring and many others have been working on improving testing options. Earlier this summer, the World Health Organization (WHO) indicated that although our world has changed, the fundamental pillars of the response have not: political leadership, and informing, engaging and listening to communities. "Keep your distance from others, clean your hands, avoid crowded and enclosed areas, and wear a mask where recommended. Where these measures are followed, cases go down. Where they're not, cases go up," WHO explains. Responses from businesses were plenty as well. Several biotechs, as well as medical device companies, have made announcements that vaccines are being developed or testing kits are in production. 

Optec International, Inc. (OTC: OPTI) announced today breaking news that, "the Company now has a suite of air purification products that effectively kills 99.99% of virus, bacteria, germs, and other harmful contaminants based on SGS testing (the world's leading inspection, verification, testing and certification company). Specifically, the Optec Hydroxyl Air Sterilizer is safe to use while children and adults are in the same room or vehicle and utilizes OH radicals triggered by built in UVC light to transform virus proteins, thereby decomposing bacteria and viruses. It is a safe, quiet, and fast sterilizer for airborne, surface and materials sterilization that is perfectly suited for both the home and office spaces. 

Additionally, the OPTEC Rovers 1, 2, and 3 use medical grade UV technology to sterilize 1,000 sq. ft., 2,000 sq. ft., and 3,000 sq. ft. spaces respectively. The Rover 1 is an ideal soliton for classrooms and hospital rooms between 500-1,000 sq. ft, and the Rovers 3 and 4 are the perfect sterilization solution for larger spaces such as warehouses, gyms, auditoriums, conference areas  and more.

These products are especially critical in light of the recent spike in reported cases in large gathering areas including college campus's across the country. The CDC's updated guidance generates a new level of severity when it comes to air sterilization. Optec has already been providing companies, schools, police departments and countries with its UV-C sterilization products and is primed for wider distribution given the increased demand.

Optec International, Inc.'s CEO, Roger Pawson stated, 'We have recognized for quite some time the world's need for effective air purification systems and are happy to be able to provide a sophisticated, non-toxic solution to help keep people safe. While masks will continue to remain paramount to all of our safety, additional measures will need to be taken to ensure clean air within enclosed spaces. Our Rover and Hydroxyl Air Purifier products truly meet the critical need at this time.'"

Relief Therapeutics Holding AG (OTCQB: RLFTF) and NeuroRx, Inc. announced yesterday the completion of their partnership agreement for the commercialization of RLF-100™ (Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world. Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories. Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We are pleased to reach this agreement with NeuroRx, a partner we believe is best suited to ensure rapid clinical development as well as timely and expedient interaction with regulatory authorities in what is likely to be the most important market for the drug, the United States. We are looking forward to collaboratively and productively working together in order to maximize the value of the overall franchise for our shareholders and get this potentially life-saving drug to patients as swiftly as possible."

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced last week that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19.  The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's TNX-1800, which is a live replicating, attenuated virus vaccine designed to protect against COVID-19. "This represents a significant milestone for the Company as the data we plan to collect from recovered and asymptomatic COVID-19 volunteers in this study will help inform vaccine development on how to safely provide the same immune responses that others got from recovering from actual SARS-CoV-2 infection," said Seth Lederman, M.D., President and CEO of Tonix.  "Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.  The features of a protective immune response to SARS-CoV-2 remain unknown.  But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important, if not dominant, role in protecting against serious illness from COVID-19."

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced back in June that it had entered into a co-promotion partnership with Indegene Inc. to establish multichannel digital marketing programs throughout the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eligible to prescribe Titan's Probuphine® (buprenorphine) implant. "This partnership with Indegene further strengthens and expands our Probuphine commercial operations, especially with the COVID-19-related restrictions that have limited in-person HCP outreach capabilities," said Titan's President and CEO, Sunil Bhonsle. "Indegene brings a wealth of business expertise and experience in the digital arena working globally with large and small pharmaceutical companies that is invaluable in today's changing environment. This partnership accelerates the expansion of our capabilities to potentially achieve our goals and enable access to Probuphine for eligible patients suffering from OUD, especially at a time when a six-month maintenance treatment option could be very important in minimizing frequent direct contact."

Novan, Inc. (NASDAQ: NOVN) reported last month a priority pipeline update. In addition to focusing its primary efforts toward SB206, its lead product candidate for molluscum, the Company is also directing pre-IND development activities toward the ongoing in vitro work related to coronaviridae, as well as exploring the potential of its NITRICIL™ platform technology for use in an antimicrobial indication for companion animal health. "Over the course of the past few months, we have dedicated time and efforts evaluating our internal pipeline of late-stage assets, our broader dermatology platform and underlying NITRICIL™ technology. These components represent what we believe to be a solid foundation to build momentum and support Novan's next phase of growth," commented Paula Brown Stafford, Chairman, President and Chief Executive Officer of Novan. "We are focused on successfully executing our pivotal Phase 3 study of SB206 for the treatment of molluscum, which is now underway and dosing patients, and are pleased with the progress our team has continued to make in this important program."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Optec International, Inc. video production, filming editing, news reporting, financial and corporate news dissemination, has been compensated Five Thousand Dollars by Cambridge Consulting Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Contact:


Editor Details

Last Updated: 22-Sep-2020